Impact of Canagliflozin on Renoprotection in T2DM

Slideshow

Will SGLT2 inhibitor canagliflozin prove renoprotective in T2DM patients? CANVAS study authors sought to find out.

Related Videos
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Erin Michos, MD | Credit: Johns Hopkins University
Natalie McCormick, PhD | Credit: American College of Rheumatology
Related Content
Presence of Diabetes Linked to Carpal Tunnel Syndrome Occurrence | Image Credit: Tiana/Pexels

Presence of Diabetes Linked to Carpal Tunnel Syndrome Occurrence

April 30th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: 2024 ACP Type 2 Diabetes Recommendations

April 19th 2024
Podcast
Anjali Dixit, MD, MPH | Credit: Stanford Medicine

GLP-1 Receptor Agonists Not Linked to Post-Op Respiratory Complications

April 25th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

April 17th 2024
Podcast
Carolyn J. Crandall, MD: Key Guideline Updates for Type 2 Diabetes

Carolyn J. Crandall, MD: Key Guideline Updates for Type 2 Diabetes

April 19th 2024
Article
Brendon Neuen, MBBS, PhD | Credit: X.Com

SMART-C Meta-Analysis: SGLT2 Inhibitors Reduce Cardiovascular Events

April 18th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.